PZ Cormay

PZ Cormay Total Assets

The Total Assets of PZ Cormay (CRM.WA) as of Oct 30, 2026 is 88.25 M PLN. In the previous year, Total Assets was 89.72 M PLN — a change of -1.65% (lower).

Total Assets

88.25 MPLN

YoY

-1.65%

Last updated:

Total Assets of PZ Cormay is 2025 88.25 M PLN. Total Assets of PZ Cormay was 2024 89.72 M PLN. It decreases by -1.65% lower compared to the previous year.

The PZ Cormay Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
161.50 M PLN
Jan 1, 2019
102.48 M PLN
Jan 1, 2020
93.74 M PLN
Jan 1, 2021
99.69 M PLN
Jan 1, 2022
101.98 M PLN
Jan 1, 2023
93.90 M PLN
Jan 1, 2024
89.72 M PLN
Jan 1, 2025
88.25 M PLN
The PZ Cormay Total Assets history
YEARTotal AssetsYoY
88.25 MPLN-1.65%
89.72 MPLN-4.45%
93.90 MPLN-7.92%
101.98 MPLN+2.30%
99.69 MPLN+6.34%
93.74 MPLN-8.52%
102.48 MPLN-36.55%
161.50 MPLN-7.48%
174.55 MPLN-7.26%
188.21 MPLN-17.14%
227.14 MPLN-10.58%
254.02 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PZ Cormay Stock analysis

What does PZ Cormay do? PZ Cormay SA manufactures diagnostic reagents and laboratory equipment, offering products like biochemical rapid tests, vacuette tubes, and devices including ACCENT-300, ACCENT-200, PRESTIGE 24i, LIVIA analyzers, MYTHIC 18 hematology analyzers, and IChem 100 urinalysis apparatus. The company serves clinical chemistry, hematology, electrophoresis, parasitology, cytology, coagulation, and specific protein recognition segments. Its products are distributed through Orphee SA, which acquired 100% stake in TT Management Sp z o o on September 1, 2014, to transfer Cormay group's production and distribution activities. Orphee SA, now holding full control of Cormay's operations, manages the distribution of PZ Cormay SA's diagnostic reagents and laboratory equipment. The firm's revenue comes from selling biochemical analyzers, hematology analyzers, and related products to healthcare facilities and laboratories. PZ Cormay SA's product portfolio includes drugs, biochemical rapid tests, and devices such as vacuette tubes, targeting clinical and diagnostic markets with a focus on specialized equipment for medical analysis. The company's revenue streams are derived from the sale of its analytical devices and reagents, with Orphee SA handling the distribution after the 2014 restructuring. PZ Cormay SA's products are used in clinical chemistry, hematology, and other diagnostic segments, with specific equipment like the ACCENT-300 and MYTHIC 18 being key offerings. The restructuring plan transferred production and distribution to Orphee SA, enabling streamlined operations and market access. PZ Cormay is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PZ Cormay stock

Total Assets of PZ Cormay is 88.25 M PLN in 2025.

Total Assets of PZ Cormay changed from 89.72 M PLN to 88.25 M PLN, representing a -1.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets PZ Cormay since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's PZ Cormay historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — PZ Cormay

All Key Metrics — PZ Cormay